Aptyx Acquires Medical Murray’s Facility, Forms Aptyx Interventional Systems

January 21, 2025—Aptyx, a Tempe, Arizona–based developer and manufacturer of complex components and devices for the life sciences, announced the acquisition of the Charlotte, North Carolina, facility of Medical Murray, a developer and producer of catheter-based interventional products and transcatheter implants.

The press release advised that the acquisition will become an integral part of Aptyx Interventional Systems, fortifying the company’s interventional and implantable expertise with engineering talent. Team members in Charlotte will become part of Aptyx, and Medical Murray will continue to operate separately through its two facilities in the Chicago, Illinois, metropolitan area.

According to the company, the transaction enables design and development center support and advanced manufacturing for customers and bolsters expertise in catheter-based interventional products and transcatheter solutions, including implantable stents and frames, complex catheters, and delivery systems.

Additionally, it expands the company’s ISO Class 7 footprint and brings particular expertise in biotextiles, such as expanded polytetrafluoroethylene covering for stents and frames.

By combining with Medical Murray, Aptyx will be able to provide a complete manufacturing solution for catheter-based interventional and implantable products, stated the company.

Gregg Tobin is President and CEO of Aptyx. Eric Leopold, who served as Chief Technology Officer of Medical Murray and leader of the Charlotte, North Carolina, business, will join Aptyx after the acquisition as Senior Vice President.

“This marks a significant step in our growth strategy, strengthening our interventional product capabilities and end-to-end offerings, driving innovation, and delivering greater value to our original equipment manufacturer life science customers,” commented Tobin in the company’s press release. “It is a key element of our original blueprint and just the beginning of our evolution, with much more growth to follow.”

Leopold added, “We’re committed to conquering technical challenges and delivering on-time and cost-efficient products for the structural heart, vascular, neurovascular, and other key end markets. Joining Aptyx and combining our comprehensive experience in interventional markets provides the rocket fuel for long-term growth.”